Itraconazol Stada (Itraconazole)

Itraconazole blocks the fungal enzyme lanosterol 14α‑demethylase, a key step in the production of ergosterol, an essential component of fungal cell membranes. By inhibiting ergosterol synthesis, the drug compromises membrane integrity, leading to impaired fungal growth and eventual eradication of the pathogen.

The dosage of Itraconazol Stada is determined by the prescribing clinician based on the specific infection, patient age, weight, renal and hepatic function, and other individual factors. Only a qualified healthcare professional can set the appropriate regimen and duration of therapy.

Safety data for itraconazole in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies any potential risk to the fetus or infant. Healthcare providers will evaluate the risk‑benefit profile for each patient and advise accordingly.

To request Itraconazol Stada, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Itraconazol Stada belongs to the azole class, offering broad‑spectrum activity against many yeasts and molds. Compared with older agents like fluconazole, itraconazole has enhanced activity against Aspergillus and certain dimorphic fungi, though it may have a higher potential for drug‑drug interactions due to CYP3A4 inhibition.

Store Itraconazol Stada at temperatures below 25 °C, in its original packaging, and protect it from moisture and direct sunlight. Maintaining these conditions helps preserve the tablet’s potency and stability throughout its shelf life.

Itraconazol Stada is taken orally, usually with food to improve absorption. The tablets should be swallowed whole with a full glass of water and not crushed or chewed, unless the prescribing information specifies an alternative method.

The most serious adverse events include hepatotoxicity, which can manifest as elevated liver enzymes, jaundice or hepatitis, and congestive heart failure due to fluid retention. Patients should be monitored for signs of liver dysfunction or worsening cardiac symptoms during therapy.

Itraconazol Stada is contraindicated in patients with known hypersensitivity to itraconazole or any azole antifungal. It should also be avoided in individuals with severe liver disease, uncontrolled heart failure, or when taking medications that have a major interaction risk, such as rifampin or St. John’s wort.